/

MiMedx Group, Inc.

MDXG US

MDXG USMiMedx Group, Inc.

United States Composite

6.25

USD

-0.18

(-2.88%)

0.49EPS Dil.

12.00P/E

913.19MMarket Cap

Next Earnings

April 30

Held by Insiders

3.90%

Held by Institutions

66.70%

Short % of Float

3.60%

YTD Yield

121.97%

3Y Yield

-25.87%

5Y Yield

226.97%

Capital Structure

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

ST Debt

- -

LT Borrowings

LT Finance Leases

- -

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

116

146

Market Capitalization

767

848

1,282

Working Capital

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

Total Current Assets

141

155

164

Cash, Cash Equivalents & STI

Accounts Receivable, Net

Inventories

Total Current Liabilities

Payables & Accruals

ST Debt

- -

Deferred Revenue

- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

22.80%

-1.13%

19.78%

Net Income, GAAP

0.00%

-100.26%

-435.00%

Free Cash Flow

-105.15%

-139.64%

-219.05%

Total Cash Common Dividend

- -

Total Equity

-NaN%

-894.44%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

242

2022

268

2023

321

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

-0.09

-0.03

-0.04

0.01

-0.16

2022

-0.11

-0.09

-0.02

-0.23

2023

-0.06

0.00

0.06

0.51

0.52

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Company Description

CEO: Mr. Joseph H. Capper
Full Time Employees: 895
Sector: Healthcare
Industry: Biotechnology
Address: 1775 West Oak Commons Court, NE Marietta GA United States 30062
IPO Date: Feb 12, 2008
CIK: 0001376339
Website: www.mimedx.com
Business: MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was incorporated in 2011 and is headquartered in Marietta, Georgia.

Company News

Yahoo
10 days ago
MIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30
Yahoo
15 days ago
MDXG: Legal Avenues
Tipranks
a month ago
MiMedx Group (MDXG) Receives a Buy from Northland Securities
Yahoo
a month ago
MIMEDX Provides Update on AXIOFILL® Request for Designation (“RFD”) from FDA
Yahoo
a month ago
Investing in MiMedx Group (NASDAQ:MDXG) a year ago would have delivered you a 138% gain
Tipranks
a month ago
Northland Securities Keeps Their Buy Rating on MiMedx Group (MDXG)
Yahoo
a month ago
MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing
Yahoo
a month ago
MIMEDX Introduces E-Commerce and Account Management Platform
Yahoo
2 months ago
MIMEDX Announces Appointment of Two New Independent Directors

Company Description

CEO: Mr. Joseph H. Capper
Full Time Employees: 895
Sector: Healthcare
Industry: Biotechnology
Address: 1775 West Oak Commons Court, NE Marietta GA United States 30062
IPO Date: Feb 12, 2008
CIK: 0001376339
Website: www.mimedx.com
Business: MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was incorporated in 2011 and is headquartered in Marietta, Georgia.

Company News

Yahoo
10 days ago
MIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30
Yahoo
15 days ago
MDXG: Legal Avenues
Tipranks
a month ago
MiMedx Group (MDXG) Receives a Buy from Northland Securities
Yahoo
a month ago
MIMEDX Provides Update on AXIOFILL® Request for Designation (“RFD”) from FDA
Yahoo
a month ago
Investing in MiMedx Group (NASDAQ:MDXG) a year ago would have delivered you a 138% gain
Tipranks
a month ago
Northland Securities Keeps Their Buy Rating on MiMedx Group (MDXG)
Yahoo
a month ago
MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing
Yahoo
a month ago
MIMEDX Introduces E-Commerce and Account Management Platform
Yahoo
2 months ago
MIMEDX Announces Appointment of Two New Independent Directors